Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 17/20 | 0.57 |
| ▸ | AKR1A1 | P14550 | 16/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7517303 | 0.94 | AKR1B1 (0.61) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL2098715 | 0.90 | AKR1B1 (0.70) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7186763 | 0.89 | AKR1B1 (0.58) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7751532 | 0.89 | AKR1B1 (0.58) | AKR1B1AKR1A1PTGDR2 | |
| Water SCHEMBL5501664 | 0.89 | AKR1B1 (0.69) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL6140102 | 0.87 | AKR1B1 (0.56) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7951912 | 0.85 | AKR1A1 (0.60) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7754413 | 0.84 | AKR1A1 (0.59) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7755683 | 0.82 | AKR1A1 (0.58) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL2098560 | 0.82 | AKR1B1 (0.58) | AKR1B1AKR1A1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521659-B2 | 3-(4,5,7-trifluorobenzothiazol-2-yl) methyl-indole-N-acetic acid, ethyl ester and benazepril, for example; reduces serum glucose and triglycerides; treating angiogenesis, hyperglycemia, hyperlipidemia and diabetes mellitus | INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2003-02-18 | — | — | US | claimed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | claimed |
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | claimed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | claimed |
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | AKR1B1 185/4885AKR1A1 203/4885PTGDR2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.